Abbildung 12: Patienten
This slide presents the proportion of patients who remain relapse-free during the post-T interval for both groups and is compared with the original 24 week data from EVIDENCE for the same patients who continue in the post-Transition time. Slide shows that the difference seen at 0-24 is likely due to Rx since the outcome within each group is considerably different based on dose but between doses is very different in weeks 0 to 24 but very similar once all patients on Rebif 44/44 means Rebif from start and 30/44 is Avonex to Rebif switch group.